The use of a new monoclonal antibody, BF1, which reacts in routinely fixed tissues, directed against the beta chain of the T cell antigen receptor was assessed to determine its reactivity in a variety of normal tissues as well as in a number of B and T cell tumours and other lymphoid disorders. It reacted with all five of the unequivocal T cell tumours tested. BF1 will have widespread use in the assessment of lymphoid tissues in patients with the acquired immune deficiency syndrome (AIDS) and the differential diagnosis of tumours.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.